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Abstract
The phosphatidylinositol 39 kinase (PI3K) pathway is commonly activated in breast cancer and aberrations such as PI3K
mutations are common. Recent exciting clinical trial results in advanced estrogen receptor-positive (ER) breast cancer
support mTOR activation is a major means of estrogen-independent tumor growth. Hence the means to identify a
responsive breast cancer population that would most benefit from these compounds in the adjuvant or earlier stage setting
is of high interest. Here we study PIK3CA genotype as well as a previously reported PI3K/mTOR-pathway gene signature
(PIK3CA-GS) and their ability to estimate the level of PI3K pathway activation in two clinical trials of newly diagnosed ER-
positive breast cancer patients- a total of 81 patients- one of which was randomized between letrozole and placebo vs
letrozole and everolimus. The main objectives were to correlate the baseline PIK3CA genotype and GS with the relative
change from baseline to day 15 in Ki67 (which has been shown to be prognostic in breast cancer) and phosphorylated S6
(S240) immunohistochemistry (a substrate of mTOR). In the randomized dataset, the PIK3CA-GS could identify those patients
with the largest relative decreases in Ki67 to letrozole/everolimus (R =20.43, p = 0.008) compared with letrozole/placebo
(R = 0.07, p = 0.58; interaction test p = 0.02). In a second dataset of pre-surgical everolimus alone, the PIK3CA-GS was not
significantly correlated with relative change in Ki67 (R =20.11, p = 0.37) but with relative change in phosphorlyated S6
(S240) (R =20.46, p = 0.028). PIK3CA genotype was not significantly associated with any endpoint in either datasets. Our
results suggest that the PIK3CA-GS has potential to identify those ER-positive BCs who may benefit from the addition of
everolimus to letrozole. Further evaluation of the PIK3CA-GS as a predictive biomarker is warranted as it may facilitate better
selection of responsive patient populations for mTOR inhibition in combination with letrozole.
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Introduction
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian
Target Of Rapamycin (mTOR) pathway is commonly deregulated
in breast cancer and consequently, there is intense interest in the
clinical development of agents that target this pathway [1]. The
presence of genetic aberrations such as PIK3CA mutations, PTEN
loss and HER2 amplification are frequent in breast cancer and
whilst data suggest they could predict for greater sensitivity to
PI3K pathway inhibition, not all sensitivity to PI3K inhibitors can
be explained by these markers [2,3,4]. PI3K pathway activation
has also been implicated in resistance to endocrine therapy in
patients with estrogen receptor (ER) -positive breast cancers [5].
Recent results from the BOLERO-2 trial highlight that targeting
mTOR is a viable strategy in patients with metastatic ER-positive
disease who have progressed on previous endocrine therapy with a
nonsteroidal aromatase inhibitor. The toxicity from the combina-
tion was not insignificant [6]. Hence, means to identify which ER-
positive breast cancer patients may require PI3K/mTOR
inhibition in addition to their endocrine therapy could facilitate
better selection of patient populations for treatment, particularly in
the adjuvant setting.
We have previously reported a gene signature (PIK3CA-GS)
derived from patients with estrogen receptor (ER)-positive breast
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cancer with PIK3CA kinase domain mutations which was able to
predict PIK3CA mutation status (genotype) in independent datasets
and was also associated with better outcomes in tamoxifen-treated
ER-positive breast cancers [7]. Several other investigators have
also reported that the PIK3CA mutated compared with wild-type
genotype is associated with a better prognosis, though a robust
prognostic study is yet to be performed in large clinical breast
cancer cohorts [7,8,9,10]. Whilst the mechanism for this is
unclear, at the gene expression level we observed unexpectedly low
levels of PI3K/mTOR pathway activation and increased levels of
estrogen signaling in PIK3CA mutant breast cancers. Hence, high
levels of the PIK3CA-GS in estrogen receptor (ER)-positive breast
cancer were associated with PIK3CA mutant (genotyped) breast
cancers but paradoxically low mTORC1 pathway output. This led
us to ask the question if the signature could provide an indication
of pathway activation in ER-positive breast cancer patients, how
this would compare to mutation status per se and importantly, if it
could identify patients who may benefit from addition of a PI3K/
mTOR pathway inhibitor as well as their hormonal therapy.
In this study we evaluated the ability of both PIK3CA genotype
and the PIK3CA-GS to quantify the level of PI3K/AKT/mTOR
pathway activation in a given tumor and its associations with anti-
proliferative responses in ER-positive breast cancer treated with
everolimus. The main endpoint of interest in this correlative
analysis was centrally reviewed Ki67 immunohistochemistry (IHC)
after two weeks of therapy. Both the change in percentage
positively staining Ki67 measured from baseline to day 15 whilst
on therapy, hereby referred to as ‘‘relative %Ki67 decrease’’ and
the number of patients achieving a ‘‘complete cell cycle response’’
(a day 15 absolute Ki67 value of less than one after log
transformation) were evaluated. Both of these endpoints have
been shown to be correlated with long term outcomes in ER-
positive breast cancer- ie have potential as early biomarkers of
efficacy prediction of new drugs and have been used in clinical
trials in this disease for this purpose [11,12,13,14].
Importantly, one of the data sets examined in this study
contained samples from a randomized clinical trial. This allowed
us the opportunity to determine whether a predictive association
existed between the PIK3CA-GS and the letrozole/everolimus
combination compared with the letrozole alone. A biomarker that
can identify individuals with a high chance of benefit from a drug
may ultimately have more utility in the clinic.
Materials and Methods
Patient Populations
Two independent datasets (A and B) were used for these
analyses and the patient populations have been previously
described [14,15,16]. None of the described analyses were
prospectively pre-planned in either study protocol.
Dataset A was a subset of patients from a randomized, double-
blind, placebo-controlled, multi-centre, phase II neoadjuvant trial
conducted in operable, previously untreated ER-postiive breast
cancer greater than 2 cm at diagnosis in post-menopausal women
[14]. Patients were randomly assigned to receive letrozole
(2.5 mg/daily) plus placebo or letrozole plus the allosteric
Table 1. Baseline characteristics of the two datasets used in this analysis.
Variable Dataset A (included in this analysis)
Dataset A Original phase II
population# Dataset B
Mean age (years) 68.08yrs 67.45 yrs 68.1yrs
SD 9.05 8.99 10.1
Histologic Grade
I 7 (12.1%) 18 (6.7%) 3 (13%)
II 38 (65.5%) 105 (39%) 10 (42.5%)
III 12 (20.6%) 52 (19.2%) 10 (42.5%)
unknown 1 (1.8%) 95 (35%) NA
Clinical Tumor size at baseline
,2.0 cm – – 5 (26.1%)
.2.0 cm 58 (100%) 270 (100%) 17 (73.9%)
Trial design Randomized Letrozole (2.5 mg/daily)+placebo OR; Letrozole+Everolimus (10 mg/day) Single arm everolimus (5 mg/day)
Total days of therapy 120 120 14
Total number of patients 58 (21.5% of original cohort) 270 23
Relative %Ki67 decreases
(D0-D15)
85.6±4.1%(letrozole/everolimus) 90.7% (letrozole/everolimus) 30.9±13.9%
60.8±8.55%(letrozole/placebo) 74.8% (letrozole/placebo)
No. Absolute D15 Ki67
responders (defined as
Ki67,1)**
18 (58% letrozole/everolimus) 52 (57% letrozole/everolimus) 3 (14%)
6 (22% letrozole/placebo) 25 (30% letrozole/placebo)
Frequency PIK3CA mutation 37.9% (22/58) 35.8% (76/212) 26% (6/23) $
Gene expression profiling Affymetrix GeneChips U133A As per standard
protocols (Affymetrix, Santa Clara, CA).
Illumina HumanRef -8 v2 Expression
Beadchip (Illumina, Cambridge, UK)
The second column compares the dataset A with the original previously published global trial population.
# as previously published in Baselga et al, JCO 2009 [11] (original cohort of which the Dataset A is a subset); Dataset B published by Sabine et al, BCR 2010 [13].
**As previously defined in Dowsett et al (CCR 2007) [9];
doi:10.1371/journal.pone.0053292.t001
PIK3CA-Genotype and GS as Predictive Biomarkers
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mTORC1 inhibitor everolimus (10 mg/daily), provided by
Novartis Pharma AG (Basel, Switzerland), for 4 months prior to
primary surgery. Of the original trial cohort, only 58 (21.5%)
patients had pre-treatment (or baseline) samples profiled using
Affymetrix U133A GeneChipsTM and standard protocols. One
patient was found to be ER-negative and removed from further
analysis. No major differences between this subset and the global
trial population in terms of clinical characteristics were observed
(Table 1). This randomized dataset was used to examine the
capabilities of PIK3CA genotype and the PIK3CA-mutant
associated gene signature (PIK3CA-GS) to predict benefit from
the addition of everolimus to endocrine therapy (letrozole).
Dataset B was comprised of 23 post-menopausal patients also
diagnosed with operable, previously untreated, ER-positive BC.
These patients were enrolled in a single arm, single institution pre-
surgical study to receive 5 mg of everolimus daily without
therapeutic intent for 14 days prior to definitive surgery. All 23
patients had pre-treatment (baseline) tumor samples profiled using
Illumina HumanRef-8 v2 Expression Bead-Chip (Illumina, Cam-
bridge, United Kingdom). This dataset was used to examine the
association between PIK3CA genotype and the PIK3CA-GS with
changes in phosphorylated S6, a target of everolimus, as well as
changes in Ki67, though it is unknown how changes in Ki67
induced by a mTOR inhibitor relate to prognosis in ER-positive
BC.
Endpoints
The main endpoints for this biomarker study were based on
centrally reviewed proliferative measurements of Ki67 expression
by immunohistochemistry (IHC) log transformed as previously
described by Dowsett and colleagues [11,12]. The endpoint of
primary interest was the relative percentage change, as measured
from baseline to day 15 post-treatment (i.e. relative %Ki67
decrease). Anti-proliferative response, as measured by reduction in
Ki67 expression to a natural logarithm of percentage positive
staining cells of less than 1 at day 15 (‘‘absolute D15 Ki67
responders’’) was also assessed. Both Ki67 endpoints have been
shown to be predictive and prognostic in ER-positive BC treated
with endocrine therapy [11,12]. Hence, despite the difference in
treatment duration, both data sets had endpoints measured by
centrally reviewed Ki67 IHC at the same early time point (albeit a
separate pathologist for each study).
In the original trial cohort, whilst changes in tumor size
(complete and partial responses) assessed using clinical palpation
were significantly different between the letrozole/everolimus vs
letrozole/placebo arms (68.1% vs 59.1%, p= 0.0616) [14], in the
cohort used for this study, we noted that the objective response
rates were not significantly different (77.4% vs 66.7%, p= 0.323
respectively). Therefore, no associations between PIK3CA geno-
type or GS with objective tumor responses were performed.
Changes in Phosphorylated S6 (S240) using IHC
Phosphorylated levels of S6 (S240) were also measured using
IHC for dataset A and B. The methodology has been previously
described [14,15].
Calculation of the PIK3CA Mutant-related Gene Signature
(PIK3CA-GS)
Gene expression data were normalized and log-transformed
prior to analysis. The PIK3CA-GS was calculated exactly as
previously published and is essentially a weighted average of 278
probe sets using weights of +1 or21, predefined by the association
between the gene and the PIK3CA mutation status in the original
training series [7]. For dataset B, all genes were matched to Entrez
Gene IDs and mapped to Illumina probe sets prior to calculation
of the signature score. Signatures scores and Ki67 information for
both datasets are provided in Table S1. Note that high levels of the
PIK3CA-GS scores represent low mTORC1 pathway activation.
PIK3CA Mutation Analysis
PIK3CA mutation hot spot sequencing for dataset A and B has
been previously described [14,15]. For dataset A, there were 22
PIK3CA mutant (38.5%) and 35 PIK3CA WT tumors. For
dataset B, there were 6 PIK3CA mutant (26%) and 17 PIK3CA
WT. Analysis according to mutation location was not performed
given the small number of mutated samples per dataset.
Statistical Analyses
Several different analyses were planned for this biomarker
study. First, because the PIK3CA-GS was developed by distin-
guishing PIK3CA genotyped (hot spot) mutant and WT tumors, we
assessed the association between the PIK3CA-GS and PIK3CA
genotype in these two datasets. The PIK3CA-GS score was used as
a continuous variable. Receiver Operating Characteristic (ROC)
curves were constructed and predictive ability was assessed by
calculating the area under the curve (AUC) together with 95%
confidence intervals (CI) using the trapezoidal rule.
Secondly, we investigated the association between relative
%Ki67 change at day 15 from baseline and (a) PIK3CA gene
status on its own, (b) the PIK3CA-GS alone and (c) a combination
of the two variables. A linear regression approach was used for this
purpose, with log transformed Ki67 values as dependent variable,
and treatment arm, PIK3CA mutation status, the continuous
PIK3CA gene signature as independent variables. When possible in
the dataset A, responders were also defined by ‘‘absolute D15
Ki67’’ values as described above. A test for interaction was used to
verify whether the slopes of the regression lines between PIK3CA-
GS (or the coefficients of the PIK3CA mutation status) and relative
change in Ki67 (log transformed) differed according to treatment
arms. For visualization purposes, patients were ranked according
to their PIK3CA-GS score and three groups of increasing values
were obtained using the tertiles.
As an exploratory analysis, changes in percentage staining of
phosphorylated S6, one of the substrates of mTOR (pS6 S240), as
measured by IHC Histo-score between baseline and day 15 were
correlated with PIK3CA genotype and PIK3CA-GS. For the
regression line, log transformed values of pS6 were used.
Analyses were performed using SPSS version 20.0 (Chicago,
IL). All p-values were two-sided and values #0.05 were considered
significant. No correction for multiple hypotheses testing was taken
as the results were considered hypothesis generating. The
Reporting Recommendations for Tumor Marker Prognostic
Studies (REMARK) criteria were followed in this study [17]
however, the results and analyses presented in this study are
considered exploratory and require further confirmation in other
datasets.
Results
Patient Characteristics
Eighty-one patients were represented in the two clinical datasets
A and B used to assess the association of PIK3CA-GS with
mutation status and anti-proliferative response to letrozole with or
without the mTOR inhibitor everolimus or everolimus alone.
Baseline characteristics of these data sets are summarized in
Table 1.
PIK3CA-Genotype and GS as Predictive Biomarkers
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Concerning this study’s primary biological endpoint, relative
%Ki67 decrease, dataset A showed 85.664.1% in the letrozole/
everolimus compared with 60.868.55% in the letrozole/placebo
arm (p= 0.001, Table 1). This is slightly lower but still comparable
to the mean reduction of 90.7% vs. 74.8% (p= 0.0002)
respectively reported in the full trial population [14]. In dataset
B, in which patients had received everolimus alone at a lower dose,
the relative %Ki67 decrease was much smaller, 30.9613.9%
[15,16].
The number of absolute D15 Ki67 responders in dataset A was
20/31 (64.5%) in the letrozole/everolimus arm compared with 6/
27 (22%) in the letrozole/placebo arm, again comparable to the
global trial cohort. There were only three absolute D15 Ki67
responders in dataset B.
Association between PIK3CA-GS and PIK3CA Genotype
The incidence of PIK3CA mutations was 38.5% (22/58) in
dataset A and 26% (6/23) in dataset B. The PIK3CA-GS was
associated with PIK3CA mutation status in both datasets with
ROC curves evaluating the PIK3CA-GS as a continuous variable
(Figure 1A, 1B- dataset A: AUC=0.67, 95% CI:0.52–0.81;
p = 0.038; dataset B: 0.77, 95% CI:0.6–0.96; p = 0.059). Both
kinase and helical domain mutations were detected with the
signature (Figure 1C, 1D), with high levels of the GS, indicating
closer similarity to the mutant genotype consistent with our
previous study–ie signifying low levels of pathway activation [7].
PIK3CA Mutation Genotype and Analysis of Anti-
proliferative Response
Baseline Ki67 expression was not statistically different between
PIK3CA mutant and WT BCs in both datasets. In dataset A, the
mean expression was 31.8265.17% and 36.5863.8% (p= 0.34)
compared with dataset B where the mean Ki67 was 14.0863.14%
and 21.6863.08% (p= 0.45) in mutant and WT tumors respec-
tively.
The relationship between PIK3CA genotype and changes in
%Ki67 decrease was investigated. In dataset A, no significant
differences were observed in the letrozole alone arm between
patients with PIK3CA mutant and WT BCs (mean %Ki67
decrease: 48.57615.45% vs 71.368.3% respectively, p = 0.19,
Figure 2A). The mean relative %Ki67 decrease in the letrozole/
everolimus arm was similar for both PIK3CA mutant and WT
BCs (82.466.03%. vs. 90.164.8% respectively, p= 0.42); there
was no significant interaction between the two arms (p = 0.45;
Figure 2A). In dataset B, the mean relative %Ki67 decrease to
single agent everolimus was 2.61650.17% vs 40.8467.77% in
patients with PIK3CA mutant and WT BCs respectively (p = 0.83)
(Figure 2B).
Association between PIK3CA-GS and Relative Anti-
proliferative Responses in Dataset A and B
We investigated the correlations between relative %Ki67
changes and the PIK3CA-GS using a linear regression with Ki67
values (log transformed) as dependent variable, with treatment
arm and the continuous PIK3CA GS as independent variables
(Figure 2C). A test for interaction was used to verify whether the
slope of the regression line differed between treatments. We found
that PIK3CA-GS (as a continuous variable) and relative %Ki67
decreases were associated with a significant negative trend for the
letrozole/everolimus arm (R=20.43, p = 0.008), but not the
letrozole/placebo arm (R= 0.07, p = 0.58) with a significant test
for interaction between the arms (p = 0.02). In other words, lower
PIK3CA-GS scores had the greatest reductions in %Ki67 in
letrozole/everolimus treated patients, consistent with the concept
that lower scores identified tumors with higher pathway activation.
Although Ki67 changes have shown to have prognostic value
only for endocrine therapy, for completeness, we also evaluated
the PIK3CA-GS in dataset B where single agent everolimus (5 mg/
daily) was given [15,16]. We observed no significant correlation
between PIK3CA-GS and %Ki67 decreases in this dataset
(R=20.13, p = 0.37; Figure 2D).
For improved visualization, we compared the mean %Ki67
decreases in the letrozole/placebo and letrozole/everolimus arms
by dividing the dataset A into three categories of increasing
PIK3CA-GS values (Figure 2E). As seen, the Ki67 decreases were
the largest in the combination treatment arm in patients with the
lowest PIK3CA-GS scores. We also performed the association
analysis between the PIK3CA-GS and the endpoint of achieving an
absolute D15 Ki67 response in dataset A, even though the number
of these responders were small, the results were similar (Figure 2F;
interaction p test = 0.17). In dataset B, given the small numbers no
further analyses were performed.
Combination PIK3CA-GS, PIK3CA Genotype and Anti-
proliferative Response
It was relevant then to examine the anti-proliferative response of
the PIK3CA-GS in each PIK3CA genotype to determine if a
combination of genotype and phenotype could provide improved
discrimination of responders. The results from dataset A suggest
that the PIK3CA-GS performs similarly for both PIK3CA genotypes
(Figure 3). Therefore, the data suggest that even for patients with a
PIK3CA mutation there is heterogeneity in pathway signaling - in
other words, those PIK3CA mt tumors with the lowest PIK3CA-GS
scores (high pathway output) were associated with larger
reductions in Ki67 with letrozole/everolimus compared with
letrozole alone (correlations as a continuous variable: letrozole/
everolimus R=20.36, letrozole/placebo R=0.47; interaction test
p = 0.05, Figure 3A, 3B). This pattern was similar for the PIK3CA
WT genotype (letrozole/everolimus R=20.54, letrozole/placebo
R=0.06; interaction test p = 0.07). Again, for improved visuali-
zation, tertiles of the PIK3CA-GS signature score were used for
both mutant and WT population (Figure 3C, 3D). This
demonstrates that lower levels of the PIK3CA-GS was associated
with larger Ki67 differences according to treatment arm- in other
words, better responses to letrozole/everolimus were observed
compared with letrozole/placebo consistent with increased path-
way activation.
In dataset B, given the small number of PIK3CA mutated BCs
this analysis was not performed.
Association between PIK3CA-GS and Relative Change in
Phosphorlyated-S6 (S240)
Given that anti-proliferative responses using KI67 were
developed for ER-positive BC treated with endocrine agents, we
looked at the relationship between the PIK3CA-GS, PIK3CA
genotype and changes in phosphorylated S6 (pS6 S240) detected
using IHC in the pre-surgical study cohort of dataset B (everolimus
alone). The mean change in percentage positive cells staining for
pS6 from baseline to day 15 for all patients was 79.966.24%. As
seen, there was no significant difference seen for percentage
change in pS6 according to genotype (p = 0.45, Figure 4A). In
contrast, there was a significant inverse correlation seen between
the PIK3CA-GS and changes in pS6 (R=20.46, p = 0.028
Figure 4B). Of note, there was no association between changes
in pS6 and changes in Ki67 (R= 0.09) in dataset B.
PIK3CA-Genotype and GS as Predictive Biomarkers
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In dataset A, interestingly for the combination, the relative
decrease observed for pS6 was less: the mean change was
47.464.7% in the letrozole/everolimus arm. As expected, there
was minimal decrease for letrozole alone: 0.3365.7%. There was
no significant difference in the relative change in pS6 according to
PIK3CA genotype (p= 0.51, Figure 4C). There was no significant
correlation between relative pS6 changes and PIK3CA-GS as a
continuous variable (R= 0.11). Of note, there was no association
between pS6 and the main endpoint, %Ki67 changes (R=0.008),
in the letrozole/everolimus arm.
Figure 1. Receiver Operating Characteristic (ROC) curves showing the association of the PIK3CA-GS with PIK3CA mutation status. A.
Dataset A, n = 22/58 (38.5%) AUC=0.67, 95%CI: 0.5–0.8, p = 0.04), B. Dataset B n= 6/23 (26%) AUC 0.77, 95%CI : 0.6–0.96, p = = 0.059). C and D show
the individual samples for each dataset and distinguish between sequenced kinase (exon 20- squares) and helical (exon 9-circles) mutations and wild-
type (WT-black) PIK3CA.
doi:10.1371/journal.pone.0053292.g001
PIK3CA-Genotype and GS as Predictive Biomarkers
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Figure 2. Relative change in %Ki67 from baseline to day 15 by treatment arm. According PIK3CA genotype in A dataset A; B dataset B
According to PIK3CA-GS scores by treatment arm: regression lines for relative change in %Ki67 from baseline to day 15 C dataset A; D dataset B E
Relative change in %Ki67 from baseline to day 15 by treatment arm and according to increasing tertiles of the PIK3CA-GS in dataset A; F Number of
Absolute D15 responders by treatment arm and according to increasing tertiles of the PIK3CA-GS in dataset A.
doi:10.1371/journal.pone.0053292.g002
PIK3CA-Genotype and GS as Predictive Biomarkers
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Discussion
The efforts invested into developing therapeutics targeted
against the PI3K signaling pathway have been immense due to
the knowledge that deregulation of this pathway contributes to
increased tumor growth and proliferation [18]. Equally, consid-
erable attention has been devoted to the search for molecular
predictive biomarkers of response to PI3K pathway inhibitors
[3,19]. Particularly for the ER-positive or ‘‘luminal’’ BCs, PIK3CA
mutations occur commonly and are thought to represent a logical
target population for this therapy. However, several issues have
complicated PIK3CAmutations as a predictive biomarker in BC: (i)
PIK3CA mutations have been associated with a relatively better
prognosis compared with PIK3CA wild-type BC patients [7,9], (ii)
the mutations are not associated with higher proliferation indices
or lower efficacy with hormonal therapy which would be
hypothesized from oncogenic activation of PIK3CA [8], and (iii)
PIK3CA mutant breast cell lines have been associated with
sensitivity to tamoxifen [7,20]. Hence the effect of PIK3CA
mutational activation on signaling and clinical relevance in ER-
positive BC is unclear.
Figure 3. Regression lines for relative change in %Ki67 from baseline to day 15 according to PIK3CA-GS scores by treatment arm by
PIK3CA genotype in dataset A. A PIK3CA WT; B PIK3CA mutant Relative change in %Ki67 from baseline to day 15 by treatment arm and according
to increasing tertiles of the PIK3CA-GS by PIK3CA genotype in dataset A C PIK3CA WT; D PIK3CA mutant.
doi:10.1371/journal.pone.0053292.g003
PIK3CA-Genotype and GS as Predictive Biomarkers
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Our results, whilst derived from two small studies have
important conclusions. These data support our original observa-
tions the high levels of the PIK3CA-GS is associated with the
PIK3CA mutant genotype. However, here we provide further data
to support that higher values of the PIK3CA-GS (i.e.: the mutant-
like phenotype) are associated with low levels of pathway
activation [7]. Whilst this may seem counterintuitive, this could
be related to the fact that the molecular composition of the tumors
defined as PIK3CA wild-type is unknown- in other words, there are
probably multiple other means of PI3K pathway activation that
exist in this group– or that low as opposed to high levels of
pathway activation could be enough in the luminal breast cancer
subtype for reasons yet to be fully understood- ie for example, too
high levels may result in senescence. Furthermore, in this
manuscript we report that those ER-positive BCs with lower
PIK3CA-GS scores and therefore higher levels pathway activation
had greater %Ki67 reductions with the combination letrozole/
everolimus treatment compared with letrozole alone–in other
words, a significant interaction is seen between treatment arms.
Importantly in dataset A the early Ki67 changes were reported to
correspond with the better objective responses observed with the
combination arm letrozole/everolimus arm compared with
letrozole alone, supporting its use as a potential prognostic marker
and surrogate endpoint for neoadjuvant trials in endocrine therapy
and highlighting the potential significance of our findings
[11,12,13].
Admittedly, the results from the second dataset of single agent
everolimus alone are hard to interpret given that prognostic value
of early Ki67 changes have only been shown for endocrine therapy
and no clinical outcome data is currently available (ie no tumor
Figure 4. Associations between PIK3CA-GS and relative change in phosphorylated S6. A Dataset B: relative percentage change in pS6
(S240) as measured by IHC from baseline to day 15 according PIK3CA genotype B Regression line for relative change in pS6 from baseline to day 15
according to PIK3CA-GS in dataset B C Dataset A: Relative percentage change in phosphorylated S6 (S240) as measured by IHC from baseline to day
15 according PIK3CA genotype and treatment arm.
doi:10.1371/journal.pone.0053292.g004
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shrinkage or relapse information). As dataset B was designed to be
a pre-surgical study, it can only be concluded that everolimus was
indeed ‘‘hitting its target’’ in terms of S6 reductions and the
PIK3CA-GS (but not genotype) was correlated with these changes.
In contrast, the PIK3CA-GS (and not genotype) was associated
with Ki67 responses but not changes in pS6 in dataset A. Dataset
A involved a randomization between endocrine therapy with and
without everolimus. In dataset A, changes in Ki67 reflected the
primary endpoint results (objective decrease in tumor size),
whereas changes in phosphorylated S6 were not correlated with
clinical outcomes and seemed to indicate a purely pharmacody-
namic effect [14]. Several hypotheses are possible for why changes
in Ki67 and pS6 had different implications in these two datasets: (i)
the PIK3CA-GS is not specific to everolimus alone, but could
incorporate a measurement of estrogen signaling given that the
PIK3CA-GS was developed from ER-positive, PIK3CA mutant
BC samples– many ER-related genes are present in the gene
signature and this could explain why the signature could be
conceivably also affected by endocrine therapy and have
correlations with anti-proliferative Ki67 reductions in this context
(ii) the small sample size in dataset B limited our power to see
subtle Ki67 effects with the single agent everolimus, (iii) the
combination of letrozole/everolimus altered the effects on pS6
reductions compared with everolimus alone, (iv) different patient
populations between datasets (v) the lower dose of everolimus and
finally (vi) technical issues could all be contributing factors to these
observations [21]. Whilst further study is required to clarify the
relationship between the signature, different biomarkers and single
vs combination therapy, for this study, dataset A probably
provides the most persuasive data due to the randomization and
some clinical outcome information being available.
Importantly, whilst we cannot exclude the possibility that
PIK3CA mutation status alone could yield the same prognostic or
predictive information as the PIK3CA-GS in larger clinical trial
data sets that would have more statistical power, notably there was
no interaction seen previously in the whole trial cohort of dataset
A involving nearly 300 women [14]. Larger studies will also be
able to analyze the effects of PIK3CA mutation status and PIK3CA-
GS on more robust clinical endpoints such as survival other than
Ki67 changes. It is also possible that PIK3CA genotype may be
more predictive of sensitivity to specific PI3K or AKT inhibitors
rather than mTOR. Regardless, future phase II/III trials should
consider upfront stratification by PIK3CA genotype in order to
accurately determine efficacy in this population, especially given its
high frequency. Perhaps the combination of mutation status
(genotype) and PIK3CA-GS (phenotype) could allow optimal
therapy individualization for this particular aberration. Moreover,
PIK3CA genotype may have different implications in early vs.
metastatic settings,
HER2 negative vs. overpressing breast cancer subtypes – the
latter could imply further dependency on p110a or higher
‘‘oncogene addiction’’ to PI3K signaling.
We acknowledge that none of these analyses were prospectively
pre-planned in the study protocols and the cohort sizes were small
so the conclusions are hypothesis generating. Nevertheless, the
strengths of our analysis derive from the fact that the validation
was performed using data from prospectively designed clinical
trials - one of which was randomized. Importantly, both trials used
the same centrally reviewed Ki67 endpoint. Notably, these results
highlight the importance of prospective tumor banking, the use of
standard endpoints in clinical trials and collaboration between
academia and pharma in order to facilitate biomarker validation.
Without concerted efforts in this regard, the hope for individu-
alized cancer treatment will remain elusive. As seen, we could only
evaluate the PIK3CA-GS in two small cohorts, as correlative tumor
collection is not standard in many clinical studies. Yet, this is the
first time a PI3K pathway-related microarray-derived gene
signature has been validated in an independent randomized,
prospective clinical trial dataset for its potential as a predictive
biomarker to PI3K-pathway targeted agents.
In conclusion, whilst it is clear that many ER-positive BC
patients do well with endocrine therapy alone [14,22], recent
clinical trial data presented in the ER-positive metastatic BC
setting provide substantial support for mTOR pathway activation
as a major means of estrogen independent tumor growth in this
population [6,23]. Hence, the ability to identify which ER-positive
patients could benefit most from the combination in newly
diagnosed tumors is now crucial to understanding who needs this
combination in the adjuvant setting. Our study supports further
investigation of the PIK3CA-GS in appropriate randomized
datasets as a biomarker that could identify women who may
derive benefit from the addition of everolimus to letrozole in ER-
positive disease.
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